Novavax (FRA:NVV1) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NVV1 Novavax Inc FRA:NVV1
49 GF Score
Price €6.91
GF Value €3.32
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:NVV1
49GF Score
Novavax Inc FRA:NVV1
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novavax (FRA:NVV1) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of €6.91 is trading 108.1% above its estimated GF Value™ of €3.32. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for FRA:NVV1:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €3.32 vs. price of €6.91 (108.1% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the FRA:NVV1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
49GF Score

Get the complete analysis for FRA:NVV1

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.91
Price
€3.32
GF Value